NGeneBio Co., Ltd. (KOSDAQ:354200)
South Korea · Delayed Price · Currency is KRW 856.00
+26.00 (3.13%)
At close: Nov 13, 2026
NGeneBio Revenue
NGeneBio had revenue of 12.45B KRW in the quarter ending June 30, 2026, with 573.76% growth. This brings the company's total for the last twelve months to 41.80B, up 538.45% year-over-year. In the year 2025, NGeneBio had annual revenue of 21.24B with 278.54% growth. That makes NGeneBio the 31,079th largest company in the world by revenue and 1,959th in South Korea.
Revenue (ttm)
41.80B
Revenue Growth
+538.45%
P/S Ratio
0.33
Revenue / Employee
733.40M
Employees
57
Market Cap
13.77B
Revenue by Geography
- South Korea 17.26B 81.3%
- Overseas 3.98B 18.7%
Fiscal year ended Dec 31, 2025 See the full NGeneBio breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 21.24B | 15.63B | 278.54% |
| Dec 31, 2024 | 5.61B | 1.26B | 28.96% |
| Dec 31, 2023 | 4.35B | -6.67B | -60.51% |
| Dec 31, 2022 | 11.02B | 3.85B | 53.81% |
| Dec 31, 2021 | 7.16B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| ADBiotech | 12.57B |
| Genotech | 7.28B |
| HLB Pep | 5.54B |
| OLIPASS | 5.25B |
| Poongjeon Pharmacy CO.,LTD. | 1.54B |
| Angiolab | 702.62M |
| Progen | 450.00M |
| Epibiotech | 449.62M |